Summary
The pharmacokinetics of oral terguride 1 mg was evaluated in a single-dose study in 8 patients with a prolactinoma and one with acromegaly. A radioreceptor assay was used to measure the plasma levels of terguride. The peak plasma concentration (2.3±0.7 ng/ml, mean±SEM) was attained within 1 h of drug administration. Moment analysis gave a mean residence time of 4.3±0.6 h. Plasma prolactin was also determined by radioimmunoassay. The plasma prolactin was reduced to 30±3% of its pretreatment value after 4 h.
This is a preview of subscription content, log in via an institution to check access.
References
Aušková M, Řežábek K, Zikán V, Semonský M (1974) Laktationshemmende Wirkung von N-D-6-Methyl-8-isoegolin-I-yl-N,N′-diethylharnstoff (VÚFB 6638). Experientia 30: 393–394
Dorow R, Breitkopf M, Gräf K-J, Horowski R (1983) Neuroendocrine effects of lisuride and its 9,10-dihydrogenated analog in healthy volunteers. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 161–174
Krause W, Dorow R, Nieuweboer B, Hasan SH (1984) Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. Eur J Clin Pharmacol 27: 335–339
Lapka R, Šmolík S, Franc Z (1984) Radioreceptor assay for ergot derivatives, transdihydrolisuride and lisurde, in biological fluids. J Pharmacol Methods 11: 263–270
Marek J (1983) Growth hormone, somatomedins and prolactin in clinical practice (In Czech). Avicenum, Prague
Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558
Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 8: 509–534
Perrier D, Mayersohn M (1982) Noncompartmental determination of steady-state volume of distribution for any mode of administration. J Pharm Sci 71: 372–373
Hümpel M, Nieuweboer B, Hasan SH, Wendt H (1981) Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: Effect on plasma prolactin level. Eur J Clin Pharmacol 20: 47–51
Flückiger E, delPozo E, von Werder K (1982) Prolactin. Physiology, pharmacology and clinical findings (Monographs on Endocrinology, Vol 23). Springer, Berlin Heidelberg New York
Flückiger E (1983) Interactions of ergot compounds with dopamine receptors and endocrine functions. J Neural Transm 18 [Suppl]: 189–204
Dorow R, Horowski R, Riedel C, Zimmermann R, Gräf K-J (1982) Transdihydrolisuride — a new ergot derivative with a potent and long-lasting prolactin lowering effect in man. Acta Endocrinol [Suppl 246] (Copenh) 99: 149
Lapka R, Pospíšil A, Sedlmayer P, Rejholec V, Řezanka V, Šmolík S, Franc Z (1985) Comparison of bioavailability of sustained-release and conventional tablets of lisuride in the dog (In Czech). Českoslov Farm 34: 3–6
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lapka, R., Marek, J., Rejholec, V. et al. Pharmacokinetics of oral terguride in patients with a prolactinoma. Eur J Clin Pharmacol 30, 363–365 (1986). https://doi.org/10.1007/BF00541546
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541546